The mechanisms by which neutralizing antibodies inhibit Marburg virus (MARV) are not known. We isolated a panel of neutralizing antibodies from a human MARV survivor that bind to MARV glycoprotein (GP) and compete for binding to a single major antigenic site. Remarkably, several of the antibodies also bind to Ebola virus (EBOV) GP. Single-particle EM structures of antibody-GP complexes reveal that all of the neutralizing antibodies bind to MARV GP at or near the predicted region of the receptor-binding site. The presence of the glycan cap or mucin-like domain blocks binding of neutralizing antibodies to EBOV GP, but not to MARV GP. The data suggest that MARV-neutralizing antibodies inhibit virus by binding to infectious virions at the exposed MARV receptor-binding site, revealing a mechanism of filovirus inhibition.
In Brief
The characterization of Marburg-specific antibodies in several patients who survived the infection reveals a common binding site in the viral glycoprotein and a mechanism for filovirus inhibition.
INTRODUCTION
Marburg virus (MARV) and Ebola virus (EBOV), which are members of the family Filoviridae, infect humans and non-human primates, causing a hemorrhagic fever with mortality rates up to 90% (Brauburger et al., 2012) . There have been a dozen outbreaks of Marburg virus infection in humans reported to date, including the most recent report from Uganda of a 30-year-old male health worker who died in September 2014 (WHO, 2014a) . As of January 7, 2015, there have been in excess of 20,000 confirmed, probable, and suspected cases of Ebola virus disease (EVD) in the current EBOV outbreak in nine affected countries (Guinea, Liberia, Mali, Nigeria, Senegal, Sierra Leone, Spain, the United Kingdom, and the United States of America), with more than 8,000 deaths (WHO, 2014b) .
There is no licensed treatment or vaccine for filovirus infection. Recently, several studies showed that filovirus glycoprotein (GP)-specific neutralizing antibodies (nAbs) can reduce mortality following experimental inoculation of animals with a lethal dose of EBOV (Dye et al., 2012; Marzi et al., 2012; Olinger et al., 2012; Qiu et al., 2012 Qiu et al., , 2014 Pettitt et al., 2013) or MARV (Dye et al., 2012) . The primary target of these nAbs, the filovirus surface GP, is a trimer composed of three heavily glycosylated GP1-GP2 heterodimers ( Figure S1 ). The GP1 subunit can be divided further into base, head, glycan cap, and mucin-like domains (Lee et al., 2008) . During viral entry, the mucin-like domain and glycan cap mediate binding to multiple host attachment factors present on the cell membrane. After the virus enters the host cell by macropinocytosis (Nanbo et al., 2010; Saeed et al., 2010) , the GP is cleaved by host proteases that remove approximately 80% of the mass of the GP1 subunit, including the mucin-like domain and glycan cap (Chandran et al., 2005; Dube et al., 2009) . After cleavage of GP in the endosome, the receptor-binding sites on GP become exposed, and the GP1 head then is able to bind to its receptor, Niemann-Pick C1 (NPC1) protein (Carette et al., 2011; Chandran et al., 2005; Cô té et al., 2011) . Subsequent conformational changes in GP facilitate fusion between viral and endosomal membranes.
The dense clustering of glycans on the glycan cap and mucinlike domain likely shield much of the surface of EBOV GP from humoral immune surveillance, leaving only a few sites on the EBOV GP protein at which nAbs could bind without interference by glycans (Cook and Lee, 2013) . Most of our knowledge about humoral response against filovirus infections has come from studies of murine Abs that recognize EBOV GP. From those studies, we learned that mouse nAbs preferentially target peptides exposed in upper, heavily glycosylated domains or lower areas (the GP1 base), where rearrangements occur that drive fusion of viral and host membranes (Saphire, 2013) . Abs have not been identified that target protein features of the GP1 head subdomain, where the receptor-binding site to NPC1 protein is located. Ab KZ52, the only reported human EBOV GP-specific mAb, was obtained from a phage display library that was constructed from bone marrow RNA obtained from a survivor (Maruyama et al., 1999) . KZ52 binds a site at the base of the GP and neutralizes EBOV, most likely by inhibiting the conformational changes required for fusion of viral and endosomal membranes (Lee et al., 2008) . Some murine Abs also have been reported to bind to the base region of Ebola virus GPs (Dias et al., 2011 , Murin et al., 2014 . In contrast, very little is known about the mechanisms by which Abs neutralize MARV. Two murine Abs that bound the mucin-like domain of MARV GP reduced MARV budding from infected cells in culture but failed to neutralize virus directly (Kajihara et al., 2012) . Polyclonal MARV-specific Abs were shown to protect non-human primates when administrated passively after challenge (Dye et al., 2012) . The epitopes recognized by such polyclonal nAbs, and the mechanism of neutralization by which these Abs act, are unknown. In this study, we isolated a large panel of human nAbs from B cells of a human survivor of severe MARV infection and used these Abs to define the molecular basis of MARV neutralization by human Abs. The results show that MARV nAbs recognize the NPC1 receptor-binding domain of MARV GP and, in some cases, also recognize conserved structural features in the equivalent receptor-binding domain on EBOV GP.
RESULTS

Isolation of Monoclonal Antibodies
We tested plasma of a MARV survivor previously infected in Uganda for the 50% neutralization activity against the Uganda strain of MARV and found a serum-neutralizing titer of 1:1,010. To generate human hybridoma cell lines secreting mAbs to MARV, we screened supernatants from EBV-transformed B cell lines derived from the survivor for binding to several recombinant forms of MARV GP or to irradiated cell lysates prepared from MARV-infected cell cultures. We fused transformed cells from B cell lines producing MARV-reactive Abs to the MARV antigens with myeloma cells and generated 51 cloned hybridomas secreting MARV-specific human mAbs. Thirty-nine of these mAbs were specific to the MARV GP, while 12 bound to infected-cell lysate, but not to GP; these latter mAbs were shown in secondary screens to bind to MARV internal proteins (NP, VP35, or VP40; data not shown). Analysis of the Ab heavy-and light-chain variable domain sequences revealed that all MARVspecific mAbs were encoded by unique Ab genes.
Neutralization Activity
To evaluate the inhibitory activity of the mAbs, we first performed in vitro neutralization studies using a chimeric vesicular stomatitis virus with MARV GP from Uganda strain on its surface (vesicular stomatitis virus/Marburg glycoprotein recombinant VSV/ GP-Uganda). Eighteen of the 39 MARV GP-specific mAbs exhibited neutralization activity against VSV/GP-Uganda (Figures 1A and 1C; Figures S2 and S4) . Of those 18 nAbs, 9 displayed strong (IC 50 < 10 mg/ml), 8 nAbs displayed moderate (IC 50 : 10-99 mg/ml), and one displayed weak (IC 50 : 100-1,000 mg/ml) neutralizing activity against VSV/GP-Uganda. We also tested the neutralization potency of all nAbs that bound to MARV GP in a plaque reduction assay using live MARV-Uganda virus. Of 18 Abs that neutralized VSV/GP-Uganda, 11 Abs exhibited neutralizing activity against MARV-Uganda (Figures 1A and 1C ; Figures S3 and S4 ). These data suggest that VSV/GP, often used to study neutralizing potency of Abs because of its BSL-2 containment level, is more susceptible to Ab-mediated neutralization than live MARV. This difference is likely explained by the significantly lower copy number of MARV GP molecules that incorporate into VSV particles compared with the large number of GP molecules on the surface of filovirus filaments (Beniac et al., 2012; Thomas et al., 1985) . Comparison of MARV-neutralizing and non-neutralizing antibodies at concentration up to 1.6 mg/ml revealed dose-dependent activity of those mAbs that neutralized. The neutralization activity of nAbs was not enhanced by the presence of complement (data not shown). As expected, we did not detect neutralizing activity for any of the 12 Abs specific to MARV NP, VP35, or VP40 proteins.
Recognition of Varying Forms of GP
To characterize the binding of isolated Abs to recombinant MARV GPs, we performed binding assays using either a recombinant MARV GP ectodomain containing the mucin-like domain (MARV GP) or a recombinant GP lacking residues 257-425 of the mucin-like domain (MARV GPDmuc). Based on OD 405 values at the highest Ab concentration tested (E max ) and 50% effective concentration (EC 50 ), we divided the MARV-GP-specific Abs into four major groups, based on binding phenotype (designated binding groups 1, 2, 3A, and 3B; Figures 1B and S5 ). Binding group 1 mAbs had an E max to GP <2 (i.e., these mAbs never exhibited a maximal binding level to MARV GP); binding group 2 mAbs had an E max to GP >2, with EC 50 for GP <EC 50 for GPDmuc (i.e., these mAbs bound to the mucin-like domain or glycan cap); and binding group 3 had an E max to GP >2, with EC 50 for GP zEC 50 for GPDmuc (i.e., these mAbs bound equally well to full-length and mucin-deleted forms of GP), with the group 3A mAbs having an EC 50 for GP <0.5 mg/ml and the group 3B mAbs having an EC 50 for GP >0.5 mg/ml (suggesting that, as a class, the group 3B mAbs possess a lower steady-state K D of binding to GP than did group 3A mAbs).
Abs that lacked neutralization activity against VSV/GPUganda or MARV-Uganda fell principally into binding groups 1, 2, and 3A. Interestingly, all VSV/GP-Uganda nAbs displayed a unique binding pattern and segregated into binding group 3B ( Figure 1C ). It was interesting that while both mAbs from groups 3A and 3B bound equally well to the full-length MARV GP and to the GPDmuc, EC 50 values for nAbs from binding group 3B were higher than those for non-neutralizing Abs from group 3A.
Competition-Binding Studies
To determine whether mAbs from distinct binding groups targeted different antigenic regions on the MARV GP surface, we performed a competition-binding assay using a real-time biosensor. We tested 18 MARV nAbs from binding group 3B, 4 Abs from binding group 3A, and 1 Ab from binding group 2 in a tandem blocking assay in which biotinylated GPDmuc was attached to a streptavidin biosensor. Abs from group 1 and the two non-neutralizing Abs from binding group 3B did not bind to biotinylated GPDmuc in the competition assay and were excluded from the analysis. While non-neutralizing Abs from binding groups 2 and 3A did not prevent binding of the binding group 3B nAbs to GPDmuc, all nAbs blocked binding of each of the other nAbs to the antigen and segregated into a single competition-binding group ( Figure 1D Group mAb VSV/GP-Uganda MARV-Uganda >  MR72  13  601  MR78  5  93  MR79  >  >  MR82  7  288  MR103  28  291  MR111  8  414  MR137  >  >  MR144  37  >  MR186  2  >  MR191  6  >  MR198  12  206  MR201  8  572  MR208  55  >  MR209  12  402  MR213  10  305  MR229  7  215  MR232  4  114  MR238 that all of the nAbs target a single major antigenic region on the MARV GP surface.
Electron Microscopy Studies of Antigen-Antibody Complexes
To determine the location of the antigenic region targeted by MARV nAbs, we performed negative stain single-particle electron microscopy (EM) studies using complexes of GPDmuc with Fab fragments of seven nAbs from Binding Group 3B. The EM reconstructions clearly showed that Fab fragments for all seven nAbs bind at the top of the GP in or near the NPC1 protein receptor-binding site (Figures 2A and 2B ). The binding pattern of these Abs could be divided further into two major groups based on their relative angle of approach to the GP head domain. MAbs MR72, MR78, MR201, and MR82 bound toward the top and side of GP1 at a shallow angle relative to the central 3-fold axis, while mAbs MR191, MR111, and MR198 bound at a steeper angle toward the top of GP1 ( Figures 2C and 2D ). When we compared IC 50 values for nAbs that bound in the two binding poses, we did not detect a significant difference in neutralization potency based on the angle of approach ( Figure 1C ).
Antibody Neutralization Escape Mutant Viruses
As an additional strategy to determine residues on MARV GP involved in binding to nAbs, we generated VSV/GP-Uganda variant viruses that escaped neutralization, and then we determined the sequence of the GP of those mAb escape viruses. Vero E6 cells were inoculated with VSV/GP-Uganda in the presence of MR72 or MR78 nAbs. Two escape mutant viruses were isolated: virus variant VSV/GP-72.5 contained three missense mutations in the MARV GP gene (N129S in the putative NPC1 receptor-binding site, S220P in the glycan cap and P455L in the (C) These antibodies can be subdivided based on their angles of approach: (1) those that bind toward the top and side of GP1 at a shallow angle relative to the central 3-fold axis (MR72 in red, MR78 in orange, MR201 in yellow, or MR82 in green) and (2) those that bind at a steeper angle toward the top of GP1 (MR191 in cyan, MR111 in blue, or MR198 in purple).
(D) The crystal structure of EBOV GPDmuc (GP1 in white and GP2 in dark gray) is modeled into the MARV GP density (mesh), and the angles of approach of the neutralizing antibodies are indicated with arrows, colored as in (B). The footprint of the antibodies is indicated by a black circle targeting residues in the putative receptor-binding site (RBS) through a variety of approach angles. See also Figure S1 .
mucin-like domain), and virus variant VSV/GP-78.1 possessed missense mutation C226Y in the glycan cap ( Figure 3A ). Consistent with the EM data, six out of seven nAbs tested displayed a higher level of neutralization activity against the wild-type VSV/ GP-Uganda than to the VSV/GP-72.5 or VSV/GP-78.1 escape mutant viruses, suggesting these nAbs recognize MARV GP in a similar fashion ( Figure 3B ). MAb MR198 exhibited equal neutralization potency against wild-type VSV/GP-Uganda or the two escape mutant viruses ( Figure 3B ). As all nAbs segregated into one competition group ( Figure 1D ), bound the MARV GP at the NPC1 receptor-binding site (Figures 2A-2D ), and displayed a similar profile of neutralization of escape mutant viruses ( Figure 3B ), we propose that blocking of MARV GP binding to NPC1 is the principal mechanism of MARV neutralization by these naturally occurring human Abs. This model is supported by the data in the accompanying paper by Hashiguchi et al. (2015; this issue of Cell) showing that MR78 inhibits binding of NPC1 domain C to MARV GP.
Cross-Reactive Binding of MARV Antibodies with EBOV GP
It is surprising that human MARV nAbs recognize the putative NPC1 protein receptor-binding site on GP, since previous studies suggested that the NPC1 protein receptor-binding site on EBOV GP may be obscured from Ab binding by the presence of the highly glycosylated glycan cap and mucin-like domain ( Lee et al., 2008) . To determine whether the MARV nAbs we isolated also could bind in a cross-reactive manner to the EBOV GP receptor-binding site, we performed ELISA using three recombinant forms of MARV and EBOV GPs: full-length GP ectodomain containing the glycan cap and mucin-like domain (designated MARV or EBOV GP), ectodomains lacking residues 257-425 (MARV) or 314-462 (EBOV) of the mucin-like domain (designated MARV or EBOV GPDmuc), and cleaved GP ectodomains enzymatically treated to remove the mucin-like domain and glycan cap (designated MARV or EBOV GPcl). Three of the MARV nAbs, designated MR78, MR111, and MR191, recognized the EBOV GPcl that lacked the glycan cap and mucin-like domain ( Figure 4A ). Remarkably, the MARV nAb MR72 bound all three forms of both EBOV and MARV GPs with similar EC 50 and E max values, indicating that its epitope, and the EBOV receptor-binding site, which it likely overlaps, might be partially accessible for Ab binding even in the full-length form ( Figure 4A ). We tested the breadth of neutralization of MARV nAbs for filoviruses using a panel of different MARV and EBOV isolates. While multiple MARV Abs displayed neutralizing activity toward different MARV strains, MARV nAbs did not exhibit detectable neutralization activity against EBOV or VSV/EBOV ( Figure 4B ). Structural analysis of MARV and EBOV GP in the accompanying paper by Hashiguchi et al. (2015) reveals that the glycan cap and mucin-like domain likely obscure the receptor-binding domain in EBOV, but not in MARV.
In Vivo Testing
We tested the in vivo protective activity of the mAbs in a murine model using mouse-adapted MARV strain Ci67 (Warfield et al., 2007 (Warfield et al., , 2009 . Inoculation of mice with MARV Ci67 causes clinical disease and, in a proportion of animals, causes lethal disease, although typically less than 100% lethality in mice (Warren et al., 2014) . We selected four of the mAbs among those with the lowest in vitro neutralization IC 50 values: MR72, MR82, MR213, and MR232. The IC 50 values in neutralization assays with MARV Uganda or mouse-adapted MARV strain Ci67 were comparable (within 2-fold). Seven-week-old BALB/c mice were injected with 100 mg of antibody by the IP route and challenged with 1,000 plaque-forming unit (PFU) of Ci67. Twenty-four hours later, antibody treatment was repeated. By day 6, all five control (untreated) mice developed progressive loss of weight and symptoms of the disease, including dyspnea, recumbency, and unresponsiveness, and on days 8 and 9, two animals were found dead and one animal was found moribund and euthanized. The remaining two animals demonstrated recovery by day 11. In contrast, all animals treated with any antibody survived and did not display the elevation of the disease score, with the exception of two animals treated with MR72, which showed a transient marginal loss of weight and increase of the disease score on days 6-9, which did not exceed 1 (Figure 5 ). The observed level of protection was remarkable given the relatively modest invitro-neutralizing potency of the antibodies.
DISCUSSION
There is an obvious urgent need for prophylactic and therapeutic interventions for filovirus infections given the recurrence of MARV outbreaks, including that in Uganda in October 2014 and a massive outbreak of EBOV infections in West Africa in 2014. There is very little information about the structural determinants of neutralization on which to base the rational selection of antibodies, and for MARV there have been no reported human nAbs.
This study reveals that naturally occurring human MARV nAbs isolated from the B cells of a recovered donor principally target the MARV NPC1 protein receptor-binding site, suggesting that a major mechanism of MARV neutralization could be inhibition of binding to receptor. Remarkably, some of the isolated antibodies also bound to the EBOV GP. This mechanism of MARV neutralization was unexpected, because previous studies with EBOV showed that the putative receptor-binding domain on GP is obscured on the surface of virions by the presence of the glycan cap and mucin-like domain, only becoming exposed following cleavage by cathepsin in the endosome. These studies suggest that the configuration of the MARV GP differs significantly from that of EBOV GP because the receptor-binding domain must be accessible for immune recognition on MARV GP. Indeed, determination of the structure of the MARV GP and structural analysis of the interaction of mAb MR78 with MARV and EBOV GP molecules shows this to be the case (see Hashiguchi et al., 2015) .
The information obtained from these studies can be used to inform development of new therapeutics and structure-based vaccine designs against filoviruses. Furthermore, as these nAbs are fully human and exhibit inhibitory activity, they might be useful as a component of a prophylactic or therapeutic approach for filovirus infection and disease. The challenge studies using a murine model here show clear evidence of in vivo activity and suggest additional preclinical studies in other species, such as guinea pigs and macaques, are warranted. Their ability to bind a broad range of MARV isolates indicates they may offer detection of or efficacy against new viral strains yet to emerge. Although some of these mAbs bind to certain forms of EBOV GP, these antibodies are not likely to be effective against natural Ebola infection because the EBOV receptorbinding site is obscured on the viral surface. However, such mAbs might neutralize EBOV if they could be delivered to the endosome, where the EBOV receptor-binding site is exposed following GP cleavage. (Smith et al., 1982) and passaged five times in Vero E6 cells. MARV strain 200501379 Angola (MARV-Angola) was isolated during the outbreak in Angola in 2005 (Towner et al., 2006) and passaged three times in Vero E6 cells. MARV Ravn virus (Ravn) was isolated from a patient in 1987 in Kenya (Johnson et al., 1996) and passaged four times in Vero E6 cells. All strains of MARV were obtained originally from the Special Pathogens Branch, U.S. Centers for Disease Control (CDC), and deposited at the World Reference Center of Emerging Viruses and Arboviruses (WRCEVA) housed at UTMB. The recombinant Ebola Zaire strain Mayinga (EBOV) expressing eGFP was generated in our laboratory by reverse genetics (Lubaki et al., 2013; Towner et al., 2005) from plasmids provided by the Special Pathogens Branch at CDC and passaged three times in Vero E6 cells. For analysis of antibody binding by ELISA, viruses were gamma-irradiated with the dose of 5 3 10 6 rad. The recombinant VSV in which the VSV/GP protein was replaced with that of MARV strain Musoke (VSV/GP-Musoke) or EBOV strain Mayinga (Garbutt et al., 2004) were provided by Dr. Thomas Geisbert (UTMB) and Dr. Heinz Feldmann (NIH), respectively; a similar virus with GP from MARV (strain 200702854 Uganda) was constructed as described below. All work with EBOV and MARV was performed within the Galveston National Laboratory BSL-4 laboratories. We used a mouse-adapted strain of MARV for testing the effect of mAbs in vivo. The mouse-adapted Ci67 strain of Marburg virus (Warfield et al., 2007) was provided by Dr. Sina Bavari (U.S. Army Medical Research Institute of Infectious Diseases) and amplified by a single passage in Vero-E6 cells.
Generation of a Chimeric Strain of VSV in which VSV G Protein Was Replaced with the GP Protein of MARV Strain Uganda
The plasmid pVSV-XN2 carrying cDNA of the full-length VSV anti-genome sequence and the support plasmids pBS-N, pBS-L, and pBS-P encoding the internal VSV proteins under control of the T7 promoter were kindly provided by Dr. John Rose (Yale University). The plasmid pC-T7, encoding the T7 polymerase, was kindly provided by Dr. Yoshihiro Kawaoka (University of Wisconsin). For generation of the VSV/GP-Uganda construct, Vero E6 cell monolayers were inoculated with MARV strain 200702854, and total cellular RNA was isolated and reverse transcribed. MARV GP open reading frame (ORF) was PCR amplified from cDNA using forward primer 5 0 -CATGTACG ACGCGTCAACATGAGGACTA-3 0 and reverse primer 5 0 -TCTAGCAGCTC GAGCTATCCAATATATTTAGTAAAGATACGACAA-3 0 (MluI and XhoI endonuclease sites are underlined, respectively; the start and end of MARV GP ORF direct and complementary sequences are italicized, respectively). To replace VSV G with MARV GP, the resulting PCR product was cloned into pVSV-XN2 using the unique MluI and XhoI endonuclease sites located between the VSV G gene-start and gene-end signals and flanking its ORF, resulting in the plasmid pVSV/GP-Uganda. To recover the recombinant virus, 1 3 10 6 BSR-T7 cells, kindly provided by Dr. Ursula Buchholz (U.S. National Institute of Allergy and Infectious Diseases), were transfected with the following plasmids: pVSV/GP-Uganda, 5 mg, pBS-N, 1.5 mg, pBS-P, 2.5 mg, pBS-L, 1 mg, and pC-T7, 5 mg. After 48 hr, transfected BSR-T7 cells were collected with a cell scraper and transferred, along with the supernates, to Vero E6 cell monolayers for amplification of the recovered VSV/GP-Uganda. 
Generation of Human Hybridomas Secreting Monoclonal Antibodies
Peripheral blood mononuclear cells (PBMCs) from the donor were isolated with Ficoll-Histopaque by density gradient centrifugation. The cells were cryopreserved immediately and stored in the vapor phase of liquid nitrogen until use. Previously cryopreserved samples were thawed, and ten million PBMCs were plated into 384-well plates (Nunc #164688) using 17 ml of cell culture medium (ClonaCell-HY Medium A, StemCell Technologies, #03801), 8 mg/ml of the TLR agonist CpG (phosphorothioate-modified oligodeoxynucleotide ZOEZOEZZZZZOEEZOEZZZT, Invitrogen), 3 mg/ml of the Chk2 inhibitor (Sigma #C3742), 1 mg/ml of cyclosporine A (Sigma #C1832), and 4.5 ml of clarified supernate from cultures of B95.8 cells (ATCC VR-1492) containing Epstein-Barr virus (EBV). After 7 days, cells from each 384-well culture plate were expanded into four 96-well culture plates (Falcon #353072) using cell culture medium containing 8 mg/ml CpG, 3 mg/ml Chk2i, and ten million irradiated heterologous human PBMCs (Nashville Red Cross) and incubated for an additional 4 days. Plates were screened for MARV antigen-specific antibodysecreting cell lines using ELISAs. Cells from wells with supernates reacting in a MARV antigen ELISA were fused with HMMA2.5 myeloma cells using an established electrofusion technique (Yu et al., 2008) . After fusion, hybridomas were resuspended in medium containing 100 mM hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT Media Supplement, Sigma #HO262), and 7 mg/ml ouabain (Sigma #O3125) and incubated for 18 days before screening hybridomas for antibody production by ELISA.
Human mAb and Fab Production and Purification
After fusion with HMMA2.5 myeloma cells, hybridomas producing MARV-specific antibodies were cloned biologically by two rounds of limiting dilution and by single-cell fluorescence-activated cell sorting. After cloning, hybridomas were expanded in post-fusion medium (ClonaCell-HY Medium E, STEMCELL Technologies #03805) until 50% confluent in 75-cm 2 flasks (Corning #430641).
For antibody production, cells from one 75-cm 2 flask were collected with a cell scraper and expanded to four 225-cm 2 flasks (Corning #431082) in serum-free medium (Hybridoma-SFM, GIBCO #12045-076). After 21 days, supernates were clarified by centrifugation and sterile filtered using 0.2-mm pore size filter devices. HiTrap Protein G or HiTrap MabSelectSure columns (GE Healthcare Life Sciences #17040501 and #11003494, respectively) were used to purify antibodies from filtered supernates. Fab fragments were generated by papain digestion (Pierce Fab Preparation Kit, Thermo Scientific #44985) and purified by chromatography using a two-column system in which the first column contained protein G resin (GE Healthcare Life Sciences #29048581) and the second column contained either anti-kappa or anti-lambda antibody light chain resins (GE Healthcare Life Sciences #17545811 and #17548211, respectively).
Expression and Purification of MARV and EBOV GPs
Angola strain MARV GP ectodomains, containing the mucin-like domain (MARV GP) or lacking residues 257-425 of the mucin-like domain (MARV GPDmuc), were used to screen supernates of transformed B cells and human hybridomas separately. Recombinant proteins for Ravn strain cleaved GP, EBOV Mayinga strain GP, EBOV Mayinga strain GPDmuc, and EBOV Mayinga strain cleaved GP were designed and expressed similarly. Large-scale production of recombinant GP or GPDmuc was performed by transfection of Drosophila Schneider 2 (S2) cells with modified pMTpuro vectors, followed by stable selection of transfected cells with 6 mg/ml puromycin. Secreted GP ectodomain expression was induced with 0.5 mM CuSO 4 for 4 days. Proteins were engineered with a modified double strep tag at the C terminus (enterokinase cleavage site followed by a strep tag/linker/strep tag) to facilitate purification using Strep-Tactin resin (QIAGEN #2-1201). Proteins were purified further by Superdex 200 size-exclusion chromatography in 10 mM Tris and 150 mM NaCl (pH 7.5) (13 TBS).
Lysates of MARV-Infected Cells
Lysates were prepared as previously described (Ksiazek et al., 1999) . Briefly, Vero E6 cell monolayers in 850 cm 2 roller bottles were inoculated with approximately 10 6 PFU MARV or EBOV and incubated at 37 C until partial destruction of monolayer occurred (approximately 9-10 days). Cell monolayers were detached using 3-mm glass beads, and cell suspensions were centrifuged at 16,000 3 g for 10 min at 4 C. Supernates were discarded; cell pellets were resuspended in 103 excess of borate buffer saline (10 mM Na 2 B 4 O 7 and 150 mM NaCl [pH 9.0]) and centrifuged at 16,000 3 g for 10 min at 4 C. Supernates were discarded; cell pellets were resuspended in cold 1% Triton X-100 (Fisher Scientific) in borate buffer saline, vortexed, and gamma-irradiated on dry ice at 5 3 10 6 rad. The lysates were sonicated with a 600 W Tekmar Sonic Disruptor TM600 (Tekmar) using a cuphorn sonicator at maximum power setting and 50% duty cycle for 10 min and centrifuged at 16,000 3 g, and the supernates were aliquoted.
Screening ELISA ELISA plates were coated with lysates of MARV-infected cells (diluted 1:1,000 in Dulbecco's PBS [DPBS]) or recombinant MARV GP or MARV GPDmuc proteins (20 mg in 10 ml DPBS per plate) and incubated at 4 C overnight. Plates were blocked with 100 ml of blocking solution/well for 1 hr. Blocking solution consisted of 10 g powdered milk, 10 ml of goat serum, 100 ml of 103 DPBS, and 0.5 ml of Tween-20 mixed to a 1 l final volume with distilled water. The presence of antibodies bound to the GP was determined using goat antihuman immunoglobulin G (IgG) horseradish peroxidase-conjugated secondary antibodies (Southern Biotech #2040-05, 1:4,000 dilution) and 1-Step Ultra TMB-ELISA substrate (Thermo Scientific #34029), with optical density read at 450 nM after stopping the reaction with 1M HCl.
Half-Maximal Effective Concentration Binding Analysis MARV or EBOV GPs, MARV or EBOV GPDmuc, or Ravn or EBOV cathepsincleaved GPs were coated onto 384-well plates (Thermo Scientific Nunc #265203) in DPBS at 2 mg/ml overnight, then antigen was removed, and plates were blocked with blocking solution made as above. Antibodies were applied to the plates at a concentration range of 1.5 mg/ml to 270 ng/ml (binding groups #1, #2, and 3A) and 0.1 mg/ml to 10 ng/ml (binding group #3B) using 3-fold serial dilutions. The presence of antibodies bound to the GP was determined using goat anti-human IgG alkaline phosphatase conjugate (Meridian Life Science #W99008A, 1:4,000 dilution) and p-nitrophenol phosphate substrate tablets (Sigma #S0942), with optical density read at 405 nM after 120 min. A non-linear regression analysis was performed on the resulting curves using Prism (v. 5) (GraphPad) to calculate EC 50 values.
MARV and EBOV Neutralization Experiments
Dilutions of mAbs in triplicate were mixed with 150 PFU of MARV or EBOV expressing eGFP in MEM containing 10% fetal bovine serum (FBS) (HyClone) and 50 mg/ml gentamicin (Cellgro #30-005-CR) with or without 5% guinea pig complement (MP Biomedicals #642836) in a total volume of 0.1 ml and incubated for 1 hr at 37 C for virus neutralization. Following neutralization, virus-antibody mixtures were placed on monolayers of Vero E6 cells in 24-well plates, incubated for 1 hr at 37 C for virus adsorption, and overlayed with MEM containing 2% FBS and 0.8% methylcellulose (Sigma-Aldrich #M0512). After incubation for 5 days, medium was removed, cells were fixed with 10% formalin (Fisher Scientific #245-684), and plates were sealed in plastic bags and incubated for 24 hr at room temperature. Sealed plates were taken out of the BSL-4 laboratory according to approved SOPs, and monolayers were washed three times with PBS. Viral plaques were immunostained with the serum of rabbits that had been hyperimmunized with MARV, or with a mAb against EBOV, clone 15H10 (BEI Resources #NR-12184). Alternatively, following virus adsorption, monolayers were covered with MEM containing 10% FBS and 1.6% tragacanth (Sigma-Aldrich #G1128). After incubation for 14 days, medium was removed, cells were fixed with 10% formalin, and plates were sealed in plastic bags, incubated for 24 hr at room temperature, and taken out of the BSL-4 laboratory as above. Fixed monolayers were stained with 10% formalin containing 0.25% crystal violet (Fisher Scientific #C581-100), and plaques were counted.
VSV-MARV and VSV-EBOV Neutralization Tests
Neutralization assays were performed in triplicate, as described above for MARV and EBOV. Following neutralization, virus-antibody mixtures were placed on monolayers of Vero E6 cells in duplicate, incubated for 1 hr at 37 C for virus adsorption, and overlayed with MEM containing 2% FBS containing 0.9% methylcellulose. After incubation for 3 days, medium was removed, monolayers were fixed and stained with 10% formalin containing 0.25% crystal violet, and plaques were counted.
Generation and Sequencing of VSV/GP-Uganda Escape Mutants
Vero E6 cell monolayers with 2-fold dilutions of mAbs (12.5-200 mg/ml) added to the medium were inoculated with 200 PFU of recombinant VSV/GP-Uganda and incubated at 37 C for 2-4 days. To determine which samples contained live virus, supernates were collected, virus was titrated in Vero E6 cell monolayers under methylcellulose overlay, monolayers were incubated at 37 C for 3-4 days, and plaques were counted. Supernates with the highest concentrations of mAbs, which were found to contain live virus by plaque titration, were incubated in presence of serially diluted mAbs, followed by titration of virus as above. The procedure was performed a total of three times. Escape mutant viruses harvested after the third passage were cloned biologically by plaque purification. For biological cloning, Vero E6 cell monolayers in 24-well plates were inoculated with dilutions of the escape mutant viruses in the presence of the corresponding mAbs (200 mg/ml of MR72 or 100 mg/ml of MR78) and covered with 0.7% low melting temperature SeaPlaque agarose (Lonza #50100). Monolayers were incubated at 37 C for 6 days; plaques were visualized with 0.01% neutral red aqueous solution (Electron Microscopy Sciences), picked, resuspended in medium, and transferred to Vero E6 cell monolayers in 24-well plates in the presence of the corresponding mAbs (200 mg/ml of MR72 or 100 mg/ml of MR78) for virus propagation. In 2-5 days, based on the extent of CPE observed, virus was harvested, and cells were dissolved in Trizol reagent (Life Technologies 315596018). Total cellular RNA was extracted, reverse transcribed, and amplified by PCR with the primers described above for generation of a chimeric strain of VSV. Two overlapping fragments covering MARV GP ORF were PCR amplified from cDNA using forward primer 5 0 -CATGTACGACGCGTCAACATGAGGACTA-3 0 and reverse primer 5 0 -ACT AAGCCCTGCTGCCAGGT-3 0 or forward primer 5 0 -ACAACAATGTACCGAGG CAA-3 0 and reverse primer 5 0 -TCTAGCAGCTCGAGCTATCCAATATATTTAG TAAAGATACGACAA-3 0 , and the nucleotide sequences of the GP ORFs were determined using standard procedures.
Analysis of Growth Kinetics of VSV/GP-Uganda Escape Mutant Viruses
Vero E6 cell monolayers in 24-well plates were inoculated in triplicate with VSV/GP-Uganda escape mutants or non-mutated virus at an MOI of 0.00025 PFU/cell in the presence of varying concentrations of the corresponding mAbs. Aliquots of medium were collected every 12 hr and frozen for titration at a later time. Titration of virus in aliquots was performed as above, without adding antibodies to the culture medium.
Biolayer Interferometry Competition Binding Assay
Biotinylated GP or GPDmuc (EZ-link Micro NHS-PEG 4 -Biotinylation Kit, Thermo Scientific #21955) (1 mg/ml) was immobilized onto streptavidin-coated biosensor tips (ForteBio #18-5019) for 2 min. After measuring the baseline signal in kinetics buffer (KB; 13 PBS, 0.01% BSA, and 0.002% Tween 20) for 2 min, biosensor tips were immersed into the wells containing primary antibody at a concentration of 100 mg/ml for 10 min. Biosensors then were immersed into wells containing competing mAbs at a concentration of 100 mg/ml for 5 min. The percent binding of the competing mAb in the presence of the first mAb was determined by comparing the maximal signal of competing mAb applied after the first mAb complex to the maximal signal of competing mAb alone. MAbs were judged to compete for binding to the same site if maximum binding of the competing mAb was reduced to <30% of its un-competed binding. MAbs were considered non-competing if maximum binding of the competing mAb was >70% of its un-competed binding. A level of 30%-70% of its un-competed binding was considered intermediate competition.
Sequence Analysis of Antibody Variable Region Genes
Total cellular RNA was extracted from clonal hybridomas that produced MARV antibodies, and RT-PCR reaction was performed using mixtures of primers designed to amplify all heavy-chain or light-chain antibody variable regions. The generated PCR products were purified and cloned into the pJet 1.2 plasmid vector (Thermo Scientific, #K1231) for sequence analysis. The nucleotide sequences of plasmid DNAs were determined using an ABI3700 automated DNA sequencer. Heavy-chain or light-chain antibody variable region sequences were analyzed using the IMGT/V-Quest program (Brochet et al., 2008; Giudicelli et al., 2011) . The analysis involved the identification of germline genes that were used for antibody production, location of complementary determining regions (CDRs), and framework regions (FRs), as well as the number and location of somatic mutations that occurred during affinity maturation.
Statistical Analysis
EC 50 values for neutralization were determined by finding the concentration of mAb at which a 50% reduction in plaque counts occurred after incubation of virus with neutralizing antibody. A logistic curve was fit to the data using the count as the outcome and the log-concentration as the predictor variable. The results of the model then were transformed back to the concentration scale. Results are presented as the concentration at the dilution that achieves a 50% reduction from challenge control with accompanying 95% confidence intervals. Each antibody was treated as a distinct analysis in a Bayesian nonlinear regression model.
Sample Preparation for EM Studies
A Ravn strain MARV GP mucin-deleted construct (GPDmuc) was produced by stable cell line expression in Drosophila S2 cells, as described above. Human Fab proteins for MARV-specific antibodies were generated as described above. Fabs were added in molar excess to GPDmuc and allowed to incubate overnight at 4 C. Complexes then were purified by Superdex 200 size-exclusion chromatography in TBS.
Electron Microscopy and Sample Preparation
A 4 ml aliquot of each complex that had been diluted to a concentration of $0.03 mg/ml with TBS buffer was placed for 15 s onto carbon-coated 400 Cu mesh grids that had been plasma cleaned for 20 s (Gatan), blotted off on the edge of the grid, and then immediately stained for 30 s with 4 ml of 2% uranyl formate. The stain was blotted off on the edge of the grid, and the grid was allowed to dry. Data were automatically collected with Leginon (Carragher et al., 2000; Potter et al., 1999; Suloway et al., 2005 ) using a FEI Tecnai F20 electron microscope operating at 120 keV with an electron dose of 30 e À /Å 2 and a magnification of 52,0003 that resulted in a pixel size of 2.65 Å at the specimen plane when collected with Tietz CMOS 4k 3 4k CCD camera. Particle orientations appeared to be generally isotropic, and images were acquired at a constant defocus value of À1.0 mm at 0 stage tilt.
Image Processing of Protein Complexes
Particles were picked automatically using DoG Picker (34) and placed into a particle stack using the Appion software (Lander et al., 2009 ). Referencefree 2D class averages were generated with the Xmipp clustering 2D alignment software (van Heel et al., 1996) and sorted into an initial 300 classes. Non-GP particles were removed, and the stack was further subclassified into classes with $100 particles per class in order to generate the final particle stack used for the reconstruction. Various numbers of class averages were chosen to create initial models using EMAN2 common lines software (Tang et al., 2007) . A model that best matched its projected classes was then used for refinement against the raw particle stack, imposing C3 symmetry, and the reconstruction was generated with ten rounds of refinement and increasingly smaller angular sampling rates with EMAN2 (Tang et al., 2007) . All model fitting and manipulation was completed using UCSF Chimera (Pettersen et al., 2004) .
In Vivo Testing
The animal protocol for testing of mAbs in mice was approved by the Institutional Animal Care and Use Committee of the University of Texas Medical Branch at Galveston. Seven-week-old BALB/c mice (Harlan) were placed in the ABSL-4 facility of the Galveston National Laboratory. Groups of mice at five animals per group were injected with individual mAbs by the intraperitoneal route twice: 1 hr prior and 24 hr after MARV challenge, using 100 mg per treatment. Untreated animals served as controls. For the challenge, mice were injected with 1,000 PFU of the mouse-adapted MARV strain Ci67 by the intraperitoneal route. Animals were weighed and monitored daily over the 3-week period after challenge. Once animals were symptomatic, they were examined twice per day. The disease was scored using the following parameters: dyspnea (possible scores 0-5), recumbency (0-9), unresponsiveness (0-5), and bleeding/hemorrhage (0-5); the individual scores for each animal were summarized.
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